Back to Journals » Drug Design, Development and Therapy » Volume 15

Pelvic Ultrasound Parameters of Long-Acting Depot Formulation of Leuprorelin in the Treatment of Idiopathic Central Precocious Puberty in Girls

Authors Yang K, Qi RF, Li RM, Zhang Y, Liu JX

Received 18 December 2020

Accepted for publication 16 March 2021

Published 7 April 2021 Volume 2021:15 Pages 1479—1484

DOI https://doi.org/10.2147/DDDT.S298155

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 1

Editor who approved publication: Dr Tuo Deng


Kun Yang,1 Rui-Fang Qi,2 Rong-Min Li,2 Yu Zhang,3 Jing-Xia Liu1

1Child Health Care Department, Baoding Children’s Hospital, Baoding, 071000, Hebei Province, People’s Republic of China; 2Endocrinology Department, Baoding Children’s Hospital, Baoding, 071000, Hebei Province, People’s Republic of China; 3Department of Science and Education, Baoding Children’s Hospital, Baoding, 071000, Hebei Province, People’s Republic of China

Correspondence: Rui-Fang Qi
Endocrinology Department, Baoding Children’s Hospital, 3399 North Hengxiang Street, Lianchi District, Baoding City, 071000, Hebei Province, People’s Republic of China
Tel +86 312 3377 771
Fax +86 312 3377 800
Email [email protected]

Objective: The present study was designed to compare the changes in ovarian and uterine parameters in girls with idiopathic central precocious puberty (ICPP) before and after gonadotropin-releasing hormone analogues (GnRHa) treatment to determine which sensitive indexes effectively reflect the therapeutic effect.
Methods: Sixty girls diagnosed with ICPP were enrolled in the present study. Relevant data were recorded before treatment. Leuprorelin acetate microspheres were injected at a dose of 30– 180 μg/(kg four weeks). Relevant parameters were measured and recorded every three months. Changes in each parameter were analyzed to evaluate the clinical effect of leuprorelin in the treatment of girls with ICPP.
Results: 1) The height grew at a constant rate. 2) The breasts retracted. 3) Changes in pelvic parameters: the volume of the ovary and uterus and major axes of the ovary, uterus, and cervix were reduced; there were no significant changes in vaginal thickness or the uterine fundal–cervical ratio (FCR). 4) Body mass index (BMI) increased.
Conclusion: Pelvic ultrasound is helpful in evaluating the efficacy of GnRHA treatment. The changes of ovarian volume and the major axes of the ovary, uterus, cervix can be used as sensitive observation indexes.

Keywords: leuprorelin microspheres, idiopathic central precocious puberty in girls, pelvic ultrasound, sensitive indicators

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]